Generalized Pustular Psoriasis Gpp Market

DelveInsight's Generalized Pustular Psoriasis (GPP) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Generalized Pustular Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Generalized Pustular Psoriasis from 2017 to 2028 segmented by the seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028


Generalized Pustular Psoriasis (GPP) - Disease Understanding and Treatment Algorithm

Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms.

GPP has been associated with abnormalities in the cytokine (messenger protein) interleukin -36-receptor-antagonist signaling. This is due to recessive IL36RN gene mutations systemic symptoms and systemic upset. GPP is characterized by recurrent acute flares and these flares may result in: headache, rapid pulse rate, loss of appetite and nausea and leg swelling.

The DelveInsight's Generalized Pustular Psoriasis market report gives the thorough understanding of the Generalized Pustular Psoriasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for GPP in the US, Europe, and Japan.


Generalized Pustular Psoriasis (GPP) - Epidemiology

The GPP epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalence Population, Gender Specific Diagnosed Prevalence Population, Age Specific Diagnosed Prevalence Population and Severity Specific Diagnosed Prevalence Population] scenario of Generalized Pustular Psoriasis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2028.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males. According to DelveInsight, total diagnosed prevalent Population of GPP in the 7MM was assessed to be more than 14,000 in 2017, which is expected to increase at a CAGR of XX% for the study period i.e. 2017-2028.

Our estimates suggests highest diagnosed prevalence of GPP in the United States with close to 6,000 cases in 2017. Furthermore, among the EU-5 countries, France had the highest diagnosed prevalent population of GPP, followed by Germany and the United Kingdom. On the other hand, Spain was assessed with the lowest diagnosed prevalent population. DelveInsight's estimations showed that Japan had 2,602 prevalent cases for GPP in 2017.

Assessments as per DelveInsight's analysts showed that the severe cases of GPP accounted for majority of the diagnosed prevalent population across 7MM countries, followed by the number of patients with moderate symptoms. However, the least number of cases were assessed for patient with mild symptoms.


Generalized Pustular Psoriasis (GPP)- Drug Chapters

This segment of the GPP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Tremfya (Guselkumab, CNTO1959) is a fully human anti-interleukin (IL)-23 HuCAL monoclonal antibody being marketed by Janssen for Generalized Pustular Psoriasis in Japan. Guselkumab is a human monoclonal IgG1? antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. Guselkumab is being developed by HuCAL antibody library technology platform under a licensing agreement of Janssen Pharmaceuticals with MorphoSys. Guselkumab is currently marketed in Japan for the treatment of Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. However, it is not approved in the United States and Europe for pustular psoriasis and erythrodermic psoriasis.

COSENTYX (Secukinumab) is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Novartis Pharmaceuticals for Generalized Pustular Psoriasis disease.

Lumicef (Brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist being marketed by Kyowa Hakko Kirin in Japan for Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis. It is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. In October 2010, Kyowa Hakko Kirin licensed from Kirin-Amgen exclusive rights to develop and commercialize brodalumab in Japan and certain other Asian countries.

Skyrizi (Risankizumab) is a humanized IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. It is being marketed by Abbvie. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of Skyrizi globally. Skyrizi is currently under review with the U.S. Food and Drug Administration (FDA) and the company expects a regulatory decision in the first half of 2019.

HUMIRA is a tumor necrosis factor (TNF) blocker being marketed by AbbVie/ Eisai for generalized pustular psoriasis and is available as a subcutaneous Injection. In plaque psoriasis, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells.

Taltz (Ixekizumab) is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor and it inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Eli Lilly and company for Pustular Psoriasis in Japan.

REMICADE (Infliximab) is a tumor necrosis factor (TNF) blocker being marketed by Mitsubishi Tanabe Pharma in Japan for Generalized Pustular Psoriasis. It neutralizes the biological activity of TNF? by binding with high affinity to the soluble and transmembrane forms of TNF? and inhibits binding of TNF? with its receptors. In January 2010 REMICADE received the approval from Ministry of Health, Labour and Welfare, Japan for additional indications including pustular psoriasis, Erythrodermic Psoriasis.


Generalized Pustular Psoriasis (GPP) - Market Outlook

The Generalized Pustular Psoriasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The market size of GPP in the seven major markets is expected to grow at a CAGR of 10.16% for the study period (2017-2028). The current therapeutic landscape of GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics and phototherapy). In EU-5 countries, for GPP, the market is same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens, and together accounted for nearly USD 20.21 million in 2017. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens.

A modest increase in market size of currently prescribed therapies has been witnessed from 2017 until the launch of emerging therapies in respective countries. The market share is expected to decline post that for current therapies, across the 7MM, owing to the increasing demand for targeted therapies to treat GPP. Among the current treatment regimens, biologics occupy the highest number of prescriptions in the treatment market of GPP. Moreover, combination therapies remain the mainstay in the treatment of GPP, irrespective of the severity of the disease.

Generalized Pustular Psoriasis (GPP)- Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of GPP market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. With this, several companies have shifted their focus toward this therapeutic area, and two of the therapies are expected to enter the treatment market of GPP during our forecast period, namely BI 655130 (Boehringer Ingelheim) and ANB019 (AnaptysBio).

Spesolimab (BI655130) is a new biological entity and first-in-class, intravenous, IL-36 receptor monoclonal antibody being in development for GPP Psoriasis by Boehringer Ingelheim. The drug candidate is the second compound being developed under the company's immunology division (after risankizumab) and has already shown strong efficacy in early clinical testing with a single dose in patients affected by GPP. The company intends to initiate a Phase III study of BI655130 in Generalized Pustular Psoriasis from May 2019.

ANB019 is an interleukin-36-receptor inhibitor monoclonal antibody being in Phase II stage of development by AnaptysBio for GPP. The drug candidate is the company's most advanced wholly-owned antibody programs which it initially developing as a potentially first-in-class therapy for patients suffering from GPP and palmoplantar pustulosis. AnaptysBio had already demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties of ANB019 in Phase I clinical trial in healthy volunteers. The company has subsequently initiated a 10-patient open-label, multi-dose, single-arm Phase II trial of ANB019 in GPP patients, also referred to as the GALLOP trial, where top-line data are anticipated in mid-2019.


Generalized Pustular Psoriasis (GPP) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Generalized Pustular Psoriasis (GPP) Report Key Strengths

• 10 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Market Size by Therapies

• Drugs Uptake


Generalized Pustular Psoriasis (GPP) Report Assessment

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Pustular Psoriasis market

• Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis market

• To understand the future market competition in the GPP market.

1. Key Insights

2. Generalized Pustular Psoriasis (GPP): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of GPP in 2017

2.2. Total Market Share (%) Distribution of GPP in 2028

3. Generalized Pustular Psoriasis (GPP): Disease Background and Overview

3.1. Generalized Pustular Psoriasis

3.2. Causes

3.3. Signs and Symptoms

3.3.1. Comorbidity

3.3.2. Complications

3.4. Genetics of Generalized Pustular Psoriasis

3.5. Types of Generalized Pustular Psoriasis

3.6. Clinical presentation

3.6.1. Histopathology

3.7. Etiology

3.8. Pathogenesis

3.8.1. Pathophysiology

3.9. Diagnosis

3.9.1. Diagnostic Criteria

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Epidemiology Forecast Assumptions

4.3. Total Diagnosed Prevalent Population of GPP in the 7MM

4.4. Gender- Specific Diagnosed Prevalence of GPP in the 7MM

4.5. Age-Specific Diagnosed Prevalent Population of GPP in the 7MM

4.6. Severity- Specific Diagnosed Prevalence of GPP in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.1.1. Total Diagnosed Prevalent Population of GPP in the United States

5.1.2. Gender- Specific Diagnosed Prevalence of GPP in the United States

5.1.3. Age-Specific Diagnosed Prevalent Population of GPP in the United States

5.1.4. Severity- Specific Diagnosed Prevalence of GPP in the United States

6. EU5 Epidemiology

6.1. Germany Epidemiology

6.1.1. Assumptions and Rationale

6.1.2. Total Diagnosed Prevalent Population of GPP in Germany

6.1.3. Gender- Specific Diagnosed Prevalence of GPP in Germany

6.1.4. Age-Specific Diagnosed Prevalent Population of GPP in Germany

6.1.5. Severity- Specific Diagnosed Prevalence of GPP in Germany

6.2. France Epidemiology

6.2.1. Assumptions and rationale

6.2.2. Total Diagnosed Prevalent Population of GPP in France

6.2.3. Gender- Specific Diagnosed Prevalence of GPP in France

6.2.4. Age-Specific Diagnosed Prevalent Population of GPP in France

6.2.5. Severity- Specific Diagnosed Prevalence of GPP in France

6.3. Italy Epidemiology

6.3.1. Assumptions and Rationale

6.3.2. Total Diagnosed Prevalent Population of GPP in Italy

6.3.3. Gender- Specific Diagnosed Prevalence of GPP in Italy

6.3.4. Age-Specific Diagnosed Prevalent Population of GPP in Italy

6.3.5. Severity- Specific Diagnosed Prevalence of GPP in Italy

6.4. Spain Epidemiology

6.4.1. Assumptions and Rationale

6.4.2. Total Diagnosed Prevalent Population of GPP in Spain

6.4.3. Gender- Specific Diagnosed Prevalence of GPP in Spain

6.4.4. Age-Specific Diagnosed Prevalent Population of GPP in Spain

6.4.5. Severity- Specific Diagnosed Prevalence of GPP in Spain

6.5. United Kingdom Epidemiology

6.5.1. Assumptions and Rationale

6.5.2. Total Diagnosed Prevalent Population of GPP in the United Kingdom

6.5.3. Gender- Specific Diagnosed Prevalence of GPP in the United Kingdom

6.5.4. Age-Specific Diagnosed Prevalent Population of GPP in the United Kingdom

6.5.5. Severity- Specific Diagnosed Prevalence of GPP in the United Kingdom

7. Japan Epidemiology

7.1. Assumptions and Rationale

7.2. Total Diagnosed Prevalent Population of GPP in Japan

7.3. Gender- Specific Diagnosed Prevalence of GPP in Japan

7.4. Age-Specific Diagnosed Prevalent Population of GPP in Japan

7.5. Severity- Specific Diagnosed Prevalence of GPP in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Treatment

8.2. Treatment segmentation as per the therapeutic classes

9. Proposed Guidelines for the Diagnosis and Treatment of GPP

9.1. Guidelines by the Medical Board of the National Psoriasis Foundation: United States

9.2. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

9.2.1. Parameters for reference in the diagnosis of GPP

9.2.2. Exclusion criteria for GPP

9.2.3. Treatments of GPP and outcomes (according to the 2010 national clinical database)

9.2.4. Summary of clinical practice guidelines recommended for GPP

10. Unmet Needs

11. Marketed Products

11.1. Tremfya: Janssen Pharmaceuticals

11.1.1. Product Description

11.1.2. Other Development Activities

11.1.3. Clinical Development

11.1.4. Safety and Efficacy

11.1.5. Advantages and Disadvantages

11.1.6. Product Profile

11.2. COSENTYX: Novartis

11.2.1. Drug Description

11.2.2. Mechanism of Action

11.2.3. Regulatory Milestones

11.2.4. Other Development Activities

11.2.5. Advantages & Disadvantages

11.2.6. Clinical Development

11.2.7. Safety and Efficacy

11.2.8. Product Profile

11.3. Lumicef: Kyowa Hakko Kirin

11.3.1. Drug Description

11.3.2. Mechanism of Action

11.3.3. Regulatory Milestones

11.3.4. Other Development Activities

11.3.5. Advantages & Disadvantages

11.3.6. Clinical Development

11.3.7. Safety and Efficacy

11.3.8. Product Profile

11.4. Skyrizi: AbbVie/Boehringer Ingelheim

11.4.1. Drug Description

11.4.2. Regulatory Milestones

11.4.3. Other Development Activities

11.4.4. Advantages & Disadvantages

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Humira: AbbVie/Eisai

11.5.1. Drug Description

11.5.2. Regulatory Milestones

11.5.3. Advantages & Disadvantages

11.5.4. Clinical Development

11.5.5. Safety and Efficacy

11.5.6. Product Profile

11.6. Taltz: Eli Lilly & Company

11.6.1. Drug Description

11.6.2. Mechanism of Action

11.6.3. Regulatory Milestones

11.6.4. Advantages & Disadvantages

11.6.5. Safety & Efficacy

11.6.6. Product Profile

11.7. Remicade: Mitsubishi Tanabe Pharma

11.7.1. Product Description

11.7.2. Mechanism of action

11.7.3. Regulatory Milestones

11.7.4. Other Development Activities

11.7.5. Advantages & Disadvantages

11.7.6. Safety & Efficacy

11.7.7. Product Profile

12. Emerging Therapies

12.1. Key Cross Competition

12.2. Spesolimab: Boehringer Ingelheim

12.2.1. Product Description

12.2.2. Clinical Development

12.2.3. Safety and Efficacy

12.2.4. Advantages and Disadvantages

12.2.5. Product Profile

12.3. Certolizumab Pegol: UCB Pharma

12.3.1. Product Description

12.3.2. Other Development Activities

12.3.3. Clinical Development

12.3.4. Advantages and Disadvantages

12.3.5. Product Profile

12.4. ANB019: AnaptysBio

12.4.1. Product Description

12.4.2. Other development Activities

12.4.3. Clinical Development

12.4.4. Safety and Efficacy

12.4.5. Advantages and Disadvantages

12.4.6. Product Profile

13. GPP: 7MM Market Analysis

13.1. Key Findings

13.2. Market Size of GPP in 7MM

13.3. Market Size of GPP by Therapies in the 7MM

14. United States: Market Outlook

14.1. United States Market Size

14.1.1. Total Market size of Generalized Pustular Psoriasis

14.1.2. Market Size of Generalized Pustular Psoriasis by Therapies in the US

15. EU-5 countries: Market Outlook

15.1. Germany Market Size

15.1.1. Total Market size of Generalized Pustular Psoriasis

15.1.2. Market Size of Generalized Pustular Psoriasis by therapies in Germany

15.2. France Market Size

15.2.1. Total Market size of Generalized Pustular Psoriasis

15.2.2. Market Size of Generalized Pustular Psoriasis by therapies in France

15.3. Italy Market Size

15.3.1. Total Market size of Generalized Pustular Psoriasis

15.3.2. Market Size of Generalized Pustular Psoriasis by therapies in Italy

15.4. Spain Market Size

15.4.1. Total Market size of Generalized Pustular Psoriasis

15.4.2. Market Size of Generalized Pustular Psoriasis by therapies in Spain

15.5. United Kingdom Market Size

15.5.1. Total Market size of Generalized Pustular Psoriasis

15.5.2. Market Size of Generalized Pustular Psoriasis by therapies in the UK

16. Japan Market Outlook

16.1. Japan Market Size

16.1.1. Total Market size of Generalized Pustular Psoriasis

16.1.2. Market Size of Generalized Pustular Psoriasis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Table 1 Diagnostic criteria for generalized pustular psoriasis

Table 2 Differential diagnosis of generalized pustular psoriasis

Table 3 Total Prevalent Population of GPP in the 7MM (2017-2028)

Table 4 Gender- Specific Diagnosed Prevalence of GPP in the 7MM (2017-2028)

Table 5 Age-Specific Diagnosed Prevalent Population of GPP in the 7MM (2017-2028)

Table 6 Severity- Specific Diagnosed Prevalence of GPP in the 7MM (2017-2028)

Table 7 Total Diagnosed Prevalent Population of GPP in the US (2017-2028)

Table 8 Gender- Specific Diagnosed Prevalence of GPP in the US (2017-2028)

Table 9 Age-Specific Diagnosed Prevalent Population of GPP in the US (2017-2028)

Table 10 Severity- Specific Diagnosed Prevalence of GPP in the United States (2017-2028)

Table 11 Total Diagnosed Prevalent Population of GPP in Germany (2017-2028)

Table 12 Gender- Specific Diagnosed Prevalence of GPP in Germany (2017-2028)

Table 13 Age-Specific Diagnosed Prevalent Population of GPP in Germany (2017-2028)

Table 14 Severity- Specific Diagnosed Prevalence of GPP in Germany (2017-2028)

Table 15 Total Diagnosed Prevalent Population of GPP in France (2017-2028)

Table 16 Gender- Specific Diagnosed Prevalence of GPP in France (2017-2028)

Table 17 Age-Specific Diagnosed Prevalent Population of GPP in France (2017-2028)

Table 18 Severity- Specific Diagnosed Prevalence of GPP in France (2017-2028)

Table 19 Total Diagnosed Prevalent Population of GPP in Italy (2017-2028)

Table 20 Gender- Specific Diagnosed Prevalence of GPP in Italy (2017-2028)

Table 21 Age-Specific Diagnosed Prevalent Population of GPP in Italy (2017-2028)

Table 22 Severity- Specific Diagnosed Prevalence of GPP in Italy (2017-2028)

Table 23 Total Diagnosed Prevalent Population of GPP in Spain (2017-2028)

Table 24 Gender- Specific Diagnosed Prevalence of GPP in Spain (2017-2028)

Table 25 Age-Specific Diagnosed Prevalent Population of GPP in Spain (2017-2028)

Table 26 Severity- Specific Diagnosed Prevalence of GPP in Spain (2017-2028)

Table 27 Total Diagnosed Prevalent Population of GPP in the United Kingdom (2017-2028)

Table 28 Gender- Specific Diagnosed Prevalence of GPP in the United Kingdom (2017-2028)

Table 29 Age-Specific Diagnosed Prevalent Population of GPP in the United Kingdom (2017-2028)

Table 30 Severity- Specific Diagnosed Prevalence of GPP in the United Kingdom (2017-2028)

Table 31 Total Diagnosed Prevalent Population of GPP in Japan (2017-2028)

Table 32 Gender- Specific Diagnosed Prevalence of GPP in Japan (2017-2028)

Table 33 Age-Specific Diagnosed Prevalent Population of GPP in Japan (2017-2028)

Table 34 Severity- Specific Diagnosed Prevalence of GPP in Japan (2017-2028)

Table 35 Recommended Dosages of etretinate in relation to severity

Table 36 Proposed doses of cyclosporin in relation to severity

Table 37 Proposed doses of MTX in relation to severity

Table 38 Proposed doses of prednisolone in relation to severity

Table 39 Proposed treatment regimen for active-type vitamin D

Table 40 Approved Treatment for GPP

Table 41 Treatment of generalized pustular psoriasis

Table 42 Levels of evidence and degree of recommendations

Table 43 Strengths of Recommendations

Table 44 Marketed Products

Table 45 Marketed Products (Contd.)

Table 46 Marketed Products (Contd.)

Table 47 Tremfya, Clinical Trial Description, 2019

Table 48 Cosentyx, Clinical Trial Description, 2019

Table 49 Lumicef, Clinical Trial Description, 2019

Table 50 Humira, Clinical Trial Description, 2019

Table 51 Key Cross Competition

Table 52 BI655130,Clinical Trial Description, 2019

Table 53 Certolizumab Pegol, Clinical Trial Description, 2019

Table 54 ANB019, Clinical Trial Description, 2019

Table 55 Market Size of GPP in 7MM in USD Million (2017-2028)

Table 56 Market Size of GOO by therapies in the 7MM, in USD Million (2017-2028)

Table 57 Treatment guidelines according to the National Psoriasis Foundation Medical Board

Table 58 Expected Launch Date of Emerging Drugs in the United States

Table 59 The US Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 60 Market Size of GPP by therapies in the United States, in USD Million (2017-2028)

Table 61 Expected Launch Date of Emerging Drugs in EU-5 countries

Table 62 Germany Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 63 Market Size of GPP by therapies in Germany, in USD Million (2017-2028)

Table 64 France Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 65 Market Size of Generalized Pustular Psoriasis by therapies in France, in USD Million (2017-2028)

Table 66 Italy Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 67 Market Size of Generalized Pustular Psoriasis by therapies in Italy, in USD Million (2017-2028)

Table 68 Spain Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 69 Market Size of Generalized Pustular Psoriasis by therapies in Spain, in USD Million (2017-2028)

Table 70 The UK Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 71 Market Size of Generalized Pustular Psoriasis by therapies in the UK, in USD Million (2017-2028)

Table 72 Key Points in the prescription of Biologics for GPP

Table 73 Status of Approved and Upcoming Treatment Regimens in Japan

Table 74 Japan Market Size of Generalized Pustular Psoriasis in USD Million (2017-2028)

Table 75 Market Size of Generalized Pustular Psoriasis by therapies in Japan, in USD Million (2017-2028)

Figure 1 Causes of Generalized Pustular Psoriasis

Figure 2 Suggested types for Generalized Pustular Psoriasis

Figure 3 Acrodermatitis continua of Hallopeau

Figure 4 Acrodermatitis continua of Hallopeau

Figure 5 Acrodermatitis continua of Hallopeau

Figure 6 Pathogenesis of GPP (main mediators) including targets for immunotherapy

Figure 7 Psoriasis and its subtypes

Figure 8 Total Prevalent Population of GPP in the 7MM (2017-2028)

Figure 9 Gender- Specific Diagnosed Prevalence of GPP in the 7MM (2017-2028)

Figure 10 Age-Specific Diagnosed Prevalent Population of GPP in the 7MM (2017-2028)

Figure 11 Severity- Specific Diagnosed Prevalence of GPP in the 7MM (2017-2028)

Figure 12 Total Diagnosed Prevalent Population of GPP in the US (2017-2028)

Figure 13 Gender- Specific Diagnosed Prevalence of GPP in the US (2017-2028)

Figure 14 Age-Specific Diagnosed Prevalent Population of GPP in the US (2017-2028)

Figure 15 Severity- Specific Diagnosed Prevalence of GPP in the United States (2017-2028)

Figure 16 Total Diagnosed Prevalent Population of GPP in Germany (2017-2028)

Figure 17 Gender- Specific Diagnosed Prevalence of GPP in Germany (2017-2028)

Figure 18 Age-Specific Diagnosed Prevalent Population of GPP in Germany (2017-2028)

Figure 19 Severity- Specific Diagnosed Prevalence of GPP in Germany (2017-2028)

Figure 20 Total Diagnosed Prevalent Population of GPP in France (2017-2028)

Figure 21 Gender- Specific Diagnosed Prevalence of GPP in France (2017-2028)

Figure 22 Age-Specific Diagnosed Prevalent Population of GPP in France (2017-2028)

Figure 23 Severity- Specific Diagnosed Prevalence of GPP in France (2017-2028)

Figure 24 Total Diagnosed Prevalent Population of GPP in Italy (2017-2028)

Figure 25 Gender- Specific Diagnosed Prevalence of GPP in Italy (2017-2028)

Figure 26 Age-Specific Diagnosed Prevalent Population of GPP in Italy (2017-2028)

Figure 27 Severity- Specific Diagnosed Prevalence of GPP in Italy (2017-2028)

Figure 28 Total Diagnosed Prevalent Population of GPP in Spain (2017-2028)

Figure 29 Gender- Specific Diagnosed Prevalence of GPP in Spain (2017-2028)

Figure 30 Age-Specific Diagnosed Prevalent Population of GPP in Spain (2017-2028)

Figure 31 Severity- Specific Diagnosed Prevalence of GPP in Spain (2017-2028)

Figure 32 Total Diagnosed Prevalent Population of GPP in the United Kingdom (2017-2028)

Figure 33 Gender- Specific Diagnosed Prevalence of GPP in the United Kingdom (2017-2028)

Figure 34 Age-Specific Diagnosed Prevalent Population of GPP in the United Kingdom (2017-2028)

Figure 35 Severity- Specific Diagnosed Prevalence of GPP in the United Kingdom (2017-2028)

Figure 36 Total Diagnosed Prevalent Population of GPP in Japan (2017-2028)

Figure 37 Gender- Specific Diagnosed Prevalence of GPP in Japan (2017-2028)

Figure 38 Age-Specific Diagnosed Prevalent Population of GPP in Japan (2017-2028)

Figure 39 Severity- Specific Diagnosed Prevalence of GPP in Japan (2017-2028)

Figure 40 Generalized Flowchart of the treatment of GPP

Figure 41 GPP Treatment segmentation as per the therapeutic classes

Figure 42 Treatment algorithm for Generalized Pustular Psoriasis (GPP)

Figure 43 Unmet Needs of Generalized Pustular Psoriasis

Figure 44 Market Size of GPP in the 7MM in USD Million (2017-2028)

Figure 45 Market Size of GPP by therapies in the 7MM, in USD Million (2017-2028)

Figure 46 Market Size of Generalized Pustular Psoriasis in the US, USD Millions (2017-2028)

Figure 47 Market Size of Generalized Pustular Psoriasis by therapies in the US, in USD Million (2017-2028)

Figure 48 Market Size of Generalized Pustular Psoriasis in Germany, USD Millions (2017-2028)

Figure 49 Market Size of GPP in Germany, in USD Million (2017-2028)

Figure 50 Market Size of Generalized Pustular Psoriasis in France, USD Millions (2017-2028)

Figure 51 Market Size of Generalized Pustular Psoriasis by therapies in France, in USD Million (2017-2028)

Figure 52 Market Size of Generalized Pustular Psoriasis in Italy, USD Millions (2017-2028)

Figure 53 Market Size of Generalized Pustular Psoriasis by therapies in Italy in USD Million (2017-2028)

Figure 54 Market Size of Generalized Pustular Psoriasis in Spain, USD Millions (2017-2028)

Figure 55 Market Size of Generalized Pustular Psoriasis by therapies in Spain in USD Million (2017-2028)

Figure 56 Market Size of Generalized Pustular Psoriasis in the UK, USD Millions (2017-2028)

Figure 57 Market Size of Generalized Pustular Psoriasis by therapies in the UK in USD Million (2017-2028)

Figure 58 Market Size of Generalized Pustular Psoriasis in Japan, USD Millions (2017-2028)

Figure 59 Market Size of Generalized Pustular Psoriasis by therapies in Japan in USD Million (2017-2028)

Figure 60 Market Drivers

Figure 61 Market Barriers

  • Tags:
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GPP...
  • Generalized Pustular Psoriasis (GP...

Forward to Friend

Need A Quote